Vanguard Group
CGTX icon

Vanguard Group’s Cognition Therapeutics CGTX Stock Holding History

Vanguard Group’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$4.48M Buy
3,317,525
+635,912
+24% +$1.03M ﹤0.01% 3294
2025
Q3 		$3.62M Buy
2,681,613
+1,377,263
+106% +$1.88M ﹤0.01% 3383
2025
Q2 		$404K Buy
1,304,350
+65,183
+5% +$22K ﹤0.01% 3967
2025
Q1 		$522K Sell
1,239,167
-400
-0% -$235 ﹤0.01% 3877
2024
Q4 		$869K Sell
1,239,567
-2,987
-0.2% -$1.48K ﹤0.01% 3808
2024
Q3 		$583K Buy
1,242,554
+95,000
+8% +$97.9K ﹤0.01% 3932
2024
Q2 		$1.9M Buy
1,147,554
+225,874
+25% +$450K ﹤0.01% 3570
2024
Q1 		$1.68M Buy
921,680
+200,126
+28% +$413K ﹤0.01% 3647
2023
Q4 		$1.33M Buy
721,554
+34,658
+5% +$45.8K ﹤0.01% 3738
2023
Q3 		$989K Buy
686,896
+18,471
+3% +$28.9K ﹤0.01% 3832
2023
Q2 		$1.22M Buy
668,425
+25,035
+4% +$53K ﹤0.01% 3839
2023
Q1 		$1.27M Buy
643,390
+98,501
+18% +$188K ﹤0.01% 3843
2022
Q4 		$1.14M Buy
544,889
+143,686
+36% +$290K ﹤0.01% 3863
2022
Q3 		$762K Buy
401,203
+330,283
+466% +$688K ﹤0.01% 4083
2022
Q2 		$150K Buy
70,920
+12,324
+21% +$31.8K ﹤0.01% 4500
2022
Q1 		$161K Buy
58,596
+17
+0% +$66 ﹤0.01% 4560
2021
Q4 		$371K Buy
+58,579
New +$571K ﹤0.01% 4482

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group's CGTX Position: Q4 2025 in Review

Vanguard Group increased its Cognition Therapeutics (CGTX) stake by 24% in Q4 2025, buying an estimated $1.03M and bringing the position to 3,317,525 shares worth $4.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3294.

Vanguard Group first reported a position in CGTX in Q4 2021 and has held it in 17 quarters since. 78 funds tracked by Wall St. Rank hold CGTX as of Q4 2025.

  • Vanguard Group held 3,317,525 shares of Cognition Therapeutics worth $4.48M as of Q4 2025.
  • Vanguard Group bought 635,912 Cognition Therapeutics shares in Q4 2025, an estimated $1.03M.
  • Cognition Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3294 holding.
  • Vanguard Group first reported a position in Cognition Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • 78 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.